Detection of human immunodeficiency virus type 1 (HIV-1) RNA in pools of sera negative for antibodies to HIV-1 and HIV-2
- PMID: 9620372
- PMCID: PMC104872
- DOI: 10.1128/JCM.36.6.1534-1538.1998
Detection of human immunodeficiency virus type 1 (HIV-1) RNA in pools of sera negative for antibodies to HIV-1 and HIV-2
Abstract
A total of 234 pools were prepared from 10,692 consecutive serum samples negative for antibodies to human immunodeficiency virus type 1 (HIV-1) and HIV-2 collected at five virological laboratories (average pool size, 45 serum samples). Pools were screened for the presence of HIV-1 RNA by a modified commercial assay (Amplicor HIV-1 Monitor test) which included an additional polyethylene glycol (PEG) precipitation step prior to purification of viral RNA (PEG Amplicor assay). The sensitivity of this assay for HIV-1 RNA detection in individual serum samples within pools matches that of standard commercial assays for individual serum samples, i.e., 500 HIV-1 RNA copies per ml. Five pools were identified as positive, and each one contained one antibody-negative, HIV-1 RNA-positive serum sample, corresponding to an average of 1 infected sample per 2,138 serum samples. Retrospective analysis revealed that the five HIV-1 RNA-positive specimens originated from individuals who had symptomatic primary HIV-1 infection at the time of sample collection and who were also positive for p24 antigenemia. We next assessed the possibility of performing the prepurification step by high-speed centrifugation (50,000 x g for 80 min) of 1.5-ml pools containing 25 microl of 60 individual serum samples, of which only 1 contained HIV-1 RNA (centrifugation Amplicor assay). The sensitivity of this assay also matches the sensitivities of standard commercial assays for HIV-1 RNA detection in individual serum samples. The results demonstrate that both assays with pooled sera can be applied to the screening of large numbers of serum samples in a time- and cost-efficient manner.
Similar articles
-
Feasibility of pooling sera for HIV-1 viral RNA to diagnose acute primary HIV-1 infection and estimate HIV incidence.AIDS. 2000 Dec 1;14(17):2751-7. doi: 10.1097/00002030-200012010-00015. AIDS. 2000. PMID: 11125894
-
Comparison of NucliSens and Amplicor monitor assays for quantification of human immunodeficiency virus type 1 (HIV-1) RNA in plasma of persons with HIV-1 subtype A infection in Abidjan, Côte d'Ivoire.J Clin Microbiol. 1998 Sep;36(9):2495-8. doi: 10.1128/JCM.36.9.2495-2498.1998. J Clin Microbiol. 1998. PMID: 9705381 Free PMC article.
-
The use of simple, rapid tests to detect antibodies to human immunodeficiency virus types 1 and 2 in pooled serum specimens.J Clin Virol. 2003 May;27(1):90-6. doi: 10.1016/s1386-6532(02)00133-6. J Clin Virol. 2003. PMID: 12727534
-
[Screening tests combined with p24 antigen and anti-HIV antibodies in early detection of HIV-1].Transfus Clin Biol. 2000 Jun;7 Suppl 1:18s-24s. doi: 10.1016/s1246-7820(00)80011-7. Transfus Clin Biol. 2000. PMID: 10919219 Review. French.
-
[Diagnostic tests: Human immunodeficiency virus type 1, type 2 (HIV-1, HIV 2)].Nihon Rinsho. 2005 Jul;63 Suppl 7:434-7. Nihon Rinsho. 2005. PMID: 16111295 Review. Japanese. No abstract available.
Cited by
-
Use of compressed sensing to expedite high-throughput diagnostic testing for COVID-19 and beyond.PLoS Comput Biol. 2022 Oct 24;18(10):e1010629. doi: 10.1371/journal.pcbi.1010629. eCollection 2022 Oct. PLoS Comput Biol. 2022. PMID: 36279287 Free PMC article.
-
Pooling saliva samples as an excellent option to increase the surveillance for SARS-CoV-2 when re-opening community settings.PLoS One. 2022 Jan 25;17(1):e0263114. doi: 10.1371/journal.pone.0263114. eCollection 2022. PLoS One. 2022. PMID: 35077513 Free PMC article.
-
Use of compressed sensing to expedite high-throughput diagnostic testing for COVID-19 and beyond.medRxiv [Preprint]. 2021 Aug 10:2021.08.09.21261669. doi: 10.1101/2021.08.09.21261669. medRxiv. 2021. Update in: PLoS Comput Biol. 2022 Oct 24;18(10):e1010629. doi: 10.1371/journal.pcbi.1010629 PMID: 34401889 Free PMC article. Updated. Preprint.
-
Systematic Review of Pooling Sputum as an Efficient Method for Xpert MTB/RIF Tuberculosis Testing during the COVID-19 Pandemic.Emerg Infect Dis. 2021 Mar;27(3):719-727. doi: 10.3201/eid2703.204090. Emerg Infect Dis. 2021. PMID: 33622482 Free PMC article.
-
Active Surveillance of Asymptomatic, Presymptomatic, and Oligosymptomatic SARS-CoV-2-Infected Individuals in Communities Inhabiting Closed or Semi-closed Institutions.Front Med (Lausanne). 2021 Feb 4;8:640688. doi: 10.3389/fmed.2021.640688. eCollection 2021. Front Med (Lausanne). 2021. PMID: 33614689 Free PMC article.
References
-
- Alaeus A, Lidman K, Sönnerborg A, Albert J. Subtype-specific problems with quantification of plasma HIV-1 RNA. AIDS. 1997;11:859–865. - PubMed
-
- Ayres L, Avillez F, Garcia-Benito A, Deinhardt F, Gurtler L, Denis F, Leonard G, Ranger S, Grob P, Joller-Jemelka H, Hess G, Seidl S, Flacke H, Simon F, Brun-Vézinet F, Sondag D, André A, Hampl H, Schoen R, Stramer S, Troonen H. Multicenter evaluation of a new recombinant enzyme immunoassay for the combined detection of antibody to HIV-1 and HIV-2. AIDS. 1990;4:131–138. - PubMed
-
- Baumberger, C., S. Kinloch-de-Loes, S. Yerly, B. Hirschel, and L. Perrin. 1993. High levels of circulating RNA in patients with symptomatic HIV-1 infection. AIDS 7(Suppl. 2):S59–S64. - PubMed
-
- Busch M P, Lee L L, Satten G A, Henrard D R, Farzadegan H, Nelson K E, Read S, Dodd R Y, Petersen L R. Time course of detection of viral and serologic markers preceding human immunodeficiency virus type 1 seroconversion: implications for screening of blood and tissue donors. Transfusion. 1995;35:91–97. - PubMed
-
- Busch M P, Couroucé A M. Relative sensitivity of United States and European assays for screening blood donors for antibodies to human immunodeficiency virus. Transfusion. 1997;37:352–353. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical

